Company | Scientific programs

Cell-O-Matic, an exciting programme about single cell genomics

Diagenode is proud to be part of this consortium that will aim at developing chip-based technologies that process DNA from individual cells, ready for Next-Generation high-throughput sequencing.

Cell-O-Matic (High Throughput Systematic Single-cell Genomics using Micro/Nano-Fluidic Chips for Extracting, Pre-analysis, Selecting and Preparing Sequence-ready DNA) consortium is made up of 13 partners-2 academic research groups, 9 SME's and 2 industries- from 8 different member states and funded by the seventh Framework FP-HEALTH.2011. This consortium will aim at developing methods that enable whole chromosome lengths of DNA to be contiguously mapped using nanofluidics. The Cell-0-Matic project will also synergize efforts to develop chip-based technologies that process DNA from individual cells, ready for Next-Generation high-throughput sequencing. Hélène Pendeville Ph.D., R&D Manager Associate noted: "Improving the quality and throughput of sequencing technologies to access genome information at a single-cell level will have a profound impact on systems biology, including cancer. Diagenode is proud to be part of this exciting 4-year programme".

Blueprint Blueprint: (for A BLUEPRINT of Hematopoietic Epigenomes) is a very ambitious and large-scale integrating project reuniting 41 partners, 52 PIs, representing 43 academic groups and 9 companies (mostly SMEs) from 12 countries over a 4-year period. Funded by the seventh Framework programme, the Blueprint consortium aims at generating 100 reference epigenomes of hematopoietic cells from healthy individuals and from leukeaemic counterparts. This will ultimately leads to the discovery and validation of epigenetic markers for diagnostic use, as well as to the dissemination of a comprehensive set of epigenetic marks to the scientific community. In a collaborative effort requiring high quality standards, all partners are commited to use their state-of-the-art technologies to provide reference epigenomes and develop experimental and computational methods to improve epigenome detection , data analysis, storage and retrieval.

For more information, http://www.blueprint-epigenome.eu

HeptromicHeptromic: (for genomic predictors and oncogenic drivers in hepatocellular carcinoma) is a 3-year translational research which aims at defining biomarkers for identification of hepatocellular carcinomas patients with poor-prognosis and novel genetic and epigenetic drivers. These research findings will be incorporated in innovative predictive tools that will contribute better refinement of therapeutic strategies. Funded by the seventh Framework programme (FP7-HEALTH.2010) it brings together experts from five different European countries and one partner from the USA, including Diagenode.

For more information, http://www.heptromic.eu

DischromThe project (in the FP7 International Training Network (Mobility project) — DisChrom — Chromatin Diseases: from basic mechanisms to therapy) is focused on the definition of the epigenome in genetic pathologies resulting from mutations in structural components of chromatin (chromatin diseases). The scope of this ITN is to promote research and training in the field of chromatin diseases. Chromatin diseases (CD) are genetic pathologies resulting from mutations in structural components of chromatin or in enzymes that biochemically modify chromatin, altering chromatin status and thereby causing drastic effects on gene expression.

For more information, http://www.dischrom.eu

atlasLed by the Second University of Naples, the ATLAS consortium includes partners in Spain, France, Romania, Lithuania, Belgium, Sweden, and the Netherlands, the ATLAS project aims at the development of Laser-Based Technologies and Prototype Instruments for Genome-Wide Chromatin Immunoprecipitation Analyses. The consortium will develop lasers that could induce DNA crosslinking for ChIP analyses of high precision and reproducibility, and extend the time range of such studies. The ATLAS consortium also will validate LaserChIP (LChIP) technologies and integrate them with irradiated frozen tissue slices and microfluidic cell sorting systems. Combining LChIP tools with proximity ligation will be used to analyze cell-selective epigenetic programs using small cell populations, down to the single-cell level. In ATLAS, Diagenode is focusing on 3 different aspects of the project:

Providing epigenetic research with high throughput technology on a genome-wide scale.

   1.   Optimization of random amplification of immunoprecipitated DNA.
   2.   Antibody production and validation.
   3.   Kit development and optimization for the research or diagnostic market.

For more information, http://www.atlas-eu.com/

 

Completed programs

Heroic


Providing epigenetic research with high throughput technology on a genome-wide scale.

Epitron



"Defining and validating the concept of "epigenetic cancer treatment."

Cancerdip


Using Methylated DNA Immunoprecipitation (MeDIP) in cancer for better clinical management.